11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Related posts

Leukaemia UK announces John Goldman Fellows for 2022

8 November 2022

Leukaemia UK announces John Goldman Fellows for 2022

Leukaemia UK has awarded their prestigious John Goldman Fellow research grants to four outstanding early-career researchers seeking to advance our understanding of and ability to treat blood cancer. Leukaemia UK…

Inquiry highlights the impact of COVID-19 on blood cancer services

11 March 2022

Inquiry highlights the impact of COVID-19 on blood cancer services

A new report has recently been published, following an inquiry by the All-Party Parliamentary Group (APPG) on Blood Cancer and the APPG on Stem Cell Transplantation and Advanced Cellular Therapies, on the impact of Covid-19 on blood cancer services in the UK.

“Who’s Cooking Dinner?” makes a spectacular return to The Dorchester

12 October 2022

“Who’s Cooking Dinner?” makes a spectacular return to The Dorchester

On 10th October 2022, Leukaemia UK’s flagship fundraising event, “Who’s Cooking Dinner?”, returned to The Dorchester Hotel. Above: Fiona Hazell, Leukaemia UK Chief Executive, Iona Beastall and Dr Kostas Tzelepis….

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

18 October 2021

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

Leukaemia UK announces five new John Goldman Fellows for 2021 to accelerate progress and stop the disease devastating lives.